Completed PHASE2 INTERVENTIONAL NCT00407264

Randomized Trial of Fluticasone in Bronchial Premalignancy

The Influence of Fluticasone Inhalation on Intermediate Markers of Carcinogenesis in the Bronchial Epithelium of a High Risk Population : A Double Blind Placebo-Controlled Randomised Phase II Study

Sponsor: Amsterdam UMC, location VUmc

Conditions Bronchogenic Carcinoma

Interventions Fluticasone propionate

Updated 6 times since 2017 Last updated: Nov 29, 2006 Started: Feb 28, 2002 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00407264, this PHASE2 trial focuses on Bronchogenic Carcinoma and remains completed. Sponsored by Amsterdam UMC, location VUmc, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amsterdam UMC, location VUmc
GlaxoSmithKline
The Netherlands Cancer Institute

Data source: Amsterdam UMC, location VUmc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands